<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476918</url>
  </required_header>
  <id_info>
    <org_study_id>21091968</org_study_id>
    <secondary_id>Insurance no.: 20-770-968594</secondary_id>
    <nct_id>NCT00476918</nct_id>
  </id_info>
  <brief_title>Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema</brief_title>
  <official_title>Dosage Dependency of Intravitreal Triamcinolone Acetonide for Treatment of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy duration of triamcinolone acetonide (steroid) for treatment of diabetic macular
      edema. Furthermore, dosage dependency of triamcinolone acetonide comparing a high dosage
      versus a low dosage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diabetic retinopathy suffer from visual acuity loss caused by diabetic macular
      edema. Intravitreal injected Triamcinolone Acetonide (steroid) reduces macular edema and
      increases visual acuity. The duration of its effect is however limited. Therefore, several
      injections are necessary.

      In this study a dosage dependency of triamcinolone acetonide (high dosage vs low dosage) is
      performed. The primary outcome parameters are the number of treatments and the efficacy of
      each injection.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">December 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity, no of treatments, duration of efficacy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure, retinal thickness</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection (triamcinolone acetonide)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetic macular edema and visual acuity between 20/200 and 20/40 age over 18 years

        Exclusion Criteria:

          -  recent treatment with laser photocoagulation or intravitreal drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jost Jonas, PhD MD</last_name>
    <role>Study Director</role>
    <affiliation>Dep of Ophthalmology, University of Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrich HM Spandau, PhD MD</last_name>
    <phone>+496213832242</phone>
    <email>ulrich.spandau@augen.ma.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Wickenhaeuser, MD</last_name>
    <phone>+496213832242</phone>
    <email>anne.wickenh√§user@augen.ma.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dep of Ophthalmology, University of Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich HM Spandau, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>May 21, 2007</last_update_submitted>
  <last_update_submitted_qc>May 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2007</last_update_posted>
  <keyword>diabetic macular edema</keyword>
  <keyword>triamcinolone acetonide</keyword>
  <keyword>intravitreal</keyword>
  <keyword>steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

